Compare GH & TXRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GH | TXRH |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.0B |
| IPO Year | 2018 | 2004 |
| Metric | GH | TXRH |
|---|---|---|
| Price | $110.09 | $183.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 17 |
| Target Price | $99.48 | ★ $191.18 |
| AVG Volume (30 Days) | ★ 1.9M | 868.8K |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 1.51% |
| EPS Growth | N/A | ★ 12.56 |
| EPS | N/A | ★ 6.55 |
| Revenue | $902,569,000.00 | ★ $5,833,958,000.00 |
| Revenue This Year | $35.00 | $11.90 |
| Revenue Next Year | $26.80 | $10.49 |
| P/E Ratio | ★ N/A | $27.57 |
| Revenue Growth | ★ 30.38 | 14.40 |
| 52 Week Low | $34.80 | $148.73 |
| 52 Week High | $113.91 | $199.99 |
| Indicator | GH | TXRH |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 66.59 |
| Support Level | $106.42 | $165.74 |
| Resistance Level | $113.91 | $182.91 |
| Average True Range (ATR) | 3.97 | 3.79 |
| MACD | 0.63 | 1.43 |
| Stochastic Oscillator | 77.16 | 99.40 |
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches.